These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Cell viability of fibroblasts to pifenidone and sirolimus: a future concept for drug eluting stents.
    Author: Walter RF, Zarogoulidis P, Mairinger FD, Werner R, Darwiche K, Zarogoulidis K, Freitag L.
    Journal: Int J Pharm; 2014 May 15; 466(1-2):38-43. PubMed ID: 24607204.
    Abstract:
    BACKGROUND: Currently one of the major problems that interventional pulmonologists have to face is the increased proliferation of fibrinous tissue on the site of the stent placement, and usually at the two ends. MATERIALS AND METHODS: The drugs rapamycin and pirfenidone were chosen for our experiment. Fibroblasts were also cultured in order to administer pirfenidone and rapamycin in different concentrations. The following cell viability methods were used: (a) Senescence - Cell Titer Assay, (b) Necrosis - Cyto Tox Assay and (c) Apoptosis - Caspase-Glo 3/7 Assay. RESULTS: Rapamycin has minimal to no effect on fibroblasts regarding apoptosis, senescence and necrosis. 0.1 to 1 μM. Pirfenidone concentrations lead to an elevated cell metabolism because cells try to evade the cytotoxic effect of the drug. Increasing Pirfenidone concentrations lead to higher apoptosis rates. 10 μM pirfenidone induces the highest apoptosis rates in this experiment and reduce cell viability to a minimum. CONCLUSION: Necrosis is unaffected by the investigated drugs.
    [Abstract] [Full Text] [Related] [New Search]